RXI PHARMACEUTICALS CORP (RXII) is a publicly traded company in the Unknown sector. Across all available filings, 26 corporate insiders have executed 357 transactions totaling $19.0M, demonstrating a bearish sentiment with -$18.5M in net insider flow. The most recent transaction on Nov 9, 2018 involved a transaction of 18,698 shares valued at $8.0K.
No significant insider buying has been recorded for RXII in the recent period.
No significant insider selling has been recorded for RXII in the recent period.
Based on recent SEC filings, insider sentiment for RXII is bearish with an Insider Alignment Score of 1/100 and a net flow of -$18.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at RXI PHARMACEUTICALS CORP (RXII) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 26 insiders are actively trading RXII stock, having executed 357 transactions in the past 90 days. The most active insider is Corp Cytrx (Executive), who has made 7 transactions totaling $17.2M.
Get notified when executives and directors at RXII file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Nov 9, 2018 | Cauwenbergh Geert | Executive | Award | 18,698 | $0.43 | $8.0K | |
| Oct 26, 2018 | Cauwenbergh Geert | Executive | Award | 18,519 | $0.44 | $8.1K | |
| Oct 12, 2018 | Cauwenbergh Geert | Executive | Award | 17,230 | $0.47 | $8.1K | |
| Sep 28, 2018 | Cauwenbergh Geert | Executive | Award | 73,587 | $1.17 | $86.1K | |
| Aug 1, 2018 | Kontulis Caitlin | Executive | Award | 10,500 | $N/A | $0 | |
| Aug 1, 2018 | Dispersyn Gerrit | Executive | Award | 16,000 | $N/A | $0 | |
| Aug 1, 2018 | Cauwenbergh Geert | Executive | Award | 21,000 | $N/A | $0 | |
| Aug 1, 2018 | J. Bitterman Robert | Executive | Award | 10,000 | $N/A | $0 | |
| Aug 1, 2018 | L. Brownlie Keith | Executive | Award | 10,000 | $N/A | $0 | |
| Aug 1, 2018 | Paul Dorman H. | Executive | Award | 10,000 | $N/A | $0 | |
| Aug 1, 2018 | E. Freeman Jonathan | Executive | Award | 10,000 | $N/A | $0 | |
| Aug 1, 2018 | Lockshin Curtis | Executive | Award | 10,000 | $N/A | $0 | |
| Oct 2, 2017 | Cauwenbergh Geert | Executive | Purchase | 200 | $0.46 | $92 | |
| Oct 2, 2017 | Cauwenbergh Geert | Executive | Purchase | 7,100 | $0.45 | $3.2K | |
| Oct 2, 2017 | Cauwenbergh Geert | Executive | Purchase | 2,700 | $0.44 | $1.2K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 99 | $18.7M | 92.0% |
Other(J) | 94 | $1.0M | 5.1% |
Award(A) | 50 | $321.4K | 1.6% |
Purchase(P) | 111 | $249.0K | 1.2% |
Exercise (Options)(X) | 1 | $16.1K | 0.1% |
Conversion(C) | 1 | $0 | 0.0% |
Gift(G) | 1 | $0 | 0.0% |
Insider selling pressure at RXI PHARMACEUTICALS CORP has increased, with 26 insiders executing 357 transactions across all time. Total sales of $18.7M significantly outpace purchases of $249.0K, resulting in a net outflow of $18.5M. This selling activity appears largely discretionary, which may warrant closer attention from investors.